TY - JOUR T1 - Although the evidence is not clear, decreases in prostate cancer mortality in specific subgroups of men may be due to screening JF - Evidence Based Medicine JO - Evid Based Med SP - 102 LP - 102 DO - 10.1136/ebmed-2015-110166 VL - 20 IS - 3 AU - Dragan Ilic AU - Philipp Dahm Y1 - 2015/06/01 UR - http://ebm.bmj.com/content/20/3/102.abstract N2 - Commentary on: Schröder F, Hugosson J, Roobol M, et al. ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027–35OpenUrlCrossRefPubMedWeb of Science.A 2013 Cochrane systematic review identified five randomised controlled trials (RCTs) examining the effectiveness of screening for prostate cancer.1 The methodology of only two RCTs was assessed to be of a low risk of bias—the European Randomised Study of Screening for Prostate Cancer (ERSPC) and the Prostate, Lung, Colorectal and Ovarian cancer screening trial.1 A meta-analysis of all five trials determined no significant difference in prostate cancer mortality in men randomised to screening versus those not invited (risk ratio, RR=1.00, 95% CI 0.86 to 1.17). With 11 years of follow-up, the ERSPC study was the only study of the five to report a significant reduction in … ER -